STOCK TITAN

EMBCV - EMBCV STOCK NEWS

Welcome to our dedicated page for EMBCV news (Ticker: EMBCV), a resource for investors and traders seeking the latest updates and insights on EMBCV stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EMBCV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EMBCV's position in the market.

Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) recently celebrated the grand opening of its new global headquarters in Parsippany, New Jersey, a significant step for the diabetes care company following its spinoff from Becton, Dickinson and Company in April 2022. The 55,600-square-foot office will house the leadership team, global support functions, and North American commercial operations, supporting approximately 2,000 employees worldwide. CEO Devdatt Kurdikar highlighted the strategic advantages of the location, including access to a skilled workforce and transportation. New Jersey Governor Phil Murphy praised Embecta's commitment to expanding the state's public health infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced that it will host a conference call on February 14, 2023, at 8:00 a.m. ET to discuss its fiscal Q1 2023 financial results and provide operational updates. Investors can join via a live webcast or teleconference. The call will include a question and answer session, and a replay will be available later that day on the company's investor relations website. As a major player in insulin delivery, Embecta aims to support people with diabetes through innovative solutions, leveraging its nearly century-long legacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) reported its financial results for the fiscal year ended September 30, 2022. Revenues decreased to $1,129.5 million, down 3.1% year-over-year. The fourth quarter saw revenues of $274.6 million, an 8.7% decline. U.S. and international revenues fell 1.5% and 4.8%, respectively. Gross profit was $774.9 million with a margin of 68.6%. Net income was $223.6 million, a sharp drop from $414.8 million the prior year, influenced by a $58.9 million impairment charge. The company announced a dividend of $0.15 per share and provided preliminary fiscal 2023 guidance of revenues between $1,050 to $1,073 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has announced a quarterly cash dividend of $0.15 per share, set to be paid on January 11, 2023. This dividend will be distributed to stockholders registered by the close of business on December 30, 2022. Embecta, a leading diabetes care company, leverages nearly a century of experience in insulin delivery to improve the lives of people living with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

Embecta Corp. (NASDAQ: EMBC) has announced its participation in the upcoming J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT / 12:45 p.m. ET. The company, known for its significant role in diabetes care, previously operated under Becton, Dickinson and Company. Interested parties can access audio webcasts of the presentation through the Company’s investor relations website. With nearly 100 years in insulin delivery, Embecta aims to enhance the lives of individuals with diabetes through innovative solutions and a dedicated workforce of over 2,000 employees worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Embecta Corp. (EMBC) and Intuity Medical announced a co-promotional agreement to market the POGO Automatic® Blood Glucose Monitoring System across the U.S., effective immediately. Embecta, a leader in diabetes care following its spin-off from BD, aims to enhance diabetes management solutions with this innovative device. POGO Automatic simplifies blood glucose testing using a 10-test cartridge technology, making it the only FDA-cleared automatic blood glucose monitor. This partnership expands Embecta's offerings while supporting Intuity's mission to improve diabetes care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on December 20, 2022, at 8:00 a.m. ET to discuss its fiscal Q4 and full-year 2022 financial results, along with preliminary guidance for fiscal year 2023. As a leading diabetes care company, Embecta aims to leverage its nearly 100-year expertise in insulin delivery to enhance life quality for diabetes patients. The call will discuss significant operational updates, and a replay will be available post-call on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) celebrated National Diabetes Awareness Month by ringing the Nasdaq Opening Bell on November 1, 2022. The event involved advocacy and professional groups focused on improving diabetes care. CEO Devdatt Kurdikar emphasized the importance of education and resources for those living with diabetes. The milestone also marks 100 years since the first successful insulin injection, highlighting the estimated 537 million people living with diabetes globally, many unaware of their condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) announced participation in two investor conferences in September 2022. The company will take part in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET in Boston, MA. Additionally, it will engage in a fireside chat at the 20th Annual Global Healthcare Conference on September 13 at 2:55 p.m. ET in New York, NY. Audio webcasts of these events will be available on the investor relations section of the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC) reported its Q3 and 9-month fiscal 2022 results, revealing revenues of $291.1 million, a 1.3% decline year-over-year. In contrast, constant currency revenue increased by 2.0%. U.S. revenue grew by 4.1% while international revenue fell by 7.1%. Net income dropped to $62.4 million from $104.7 million in the previous year. Adjusted EBITDA was $117.9 million (40.5% margin), lower than last year. The company raised its second-half guidance for constant currency revenue growth and margins, while declaring a $0.15 quarterly dividend.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the market cap of EMBCV (EMBCV)?

The market cap of EMBCV (EMBCV) is approximately 1.9B.
EMBCV

Nasdaq:EMBCV

EMBCV Rankings

EMBCV Stock Data

1.90B
Drug Manufacturers—Specialty & Generic
Healthcare
Link
United States
Parsippany